Haploidentical peripheral blood stem cell transplantation without in vitro T-cell depletion for the treatment of malignant hematological diseases

Journal of Clinical Rehabilitative Tissue Engineering Research

Volumn 13, Issue 6, 2009, Pages 1185-1190

  Yuan, Hai Long ^a   Wen, Bing Zhao ^a   Qu, Jian Hu ^a   Li, Ling ^a   Jiang, Ming ^a   Hao, Jian Ping ^a   Chen, Rong ^a   Guo, Xing Hong ^a   Halida, Yasen ^a   Wang, Shan Zheng ^a   Ding, Ling Lu ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ARTICLE; CANCER RELAPSE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG DOSE REDUCTION; FEMALE; GENE LOCUS; GRAFT FAILURE; HAPLOIDY; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HLA TYPING; HUMAN; IMMUNE STATUS; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MALE; MYELOABLATIVE CONDITIONING; OBSERVATIONAL STUDY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POSTOPERATIVE COMPLICATION; SCHOOL CHILD; STEM CELL MOBILIZATION; T CELL DEPLETION;

EID: 62549108154     PISSN: 16738225     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. State Council of the People's Republic of China. Administrative Regulations on Medical Institution. 1994-09-01.
2. Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23(15):3447-3454.
3. Walker I, Shehata N, Cantin G, et al. Canadian multicenter pilot trial of haploidentical donor transplantation. Blood Cells Mol Dis. 2004;33(3):222-226.
4. Waller EK, Giver CR, Rosenthal H, et al. Facilitating T-cell reconstitution after haploidentical transplantation in adults. Blood Cells Mol Dis. 2004;33(3):233-237.
5. Pan L, Delmonte J Jr, Jalonen CK, et al. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood. 1995;86(12):4422-4429.
6. Urbano-Ispizua A, Rozman C, Pimentel P, et al. The number of donor CD3+ cells is the most important factor for graft failure after allogeneic transplantation of CD34+ selected cells from peripheral blood from HLA-identical siblings. Blood. 2001;97(2):383-387.
7. Reisner Y,Martelli MF.Stem cell escalation enables HLA-disparate haematopoietic transplants in leukaemia patients. Immunol Today. 1999;20(8):343-347.
8. Wang HX, Ji SQ, Chen HR, et al. Clinical study on hematopoietic reconstitution in patients with leukemia by haploidentical bone marrow transplantation. Zhongguo Shiyan Xueyexue Zazhi. 2003;11(40):416-419.
9. Huang XJ, Liu DH, Liu KY, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant. 2006;38:291-297.
10. Xiao Y, Zhang HD, Zhang YC, et al. Treatment of haematological diseases by transplantation of hematopoietic stem cells from HLA-mismatched related donors. Huazhong Keji Daxue Xuebao (yixueban). 2008;37(2):262-265.
11. Sun AN, Wu DP, Wang Y, et al. Clinical study on haploid HLA-matched hematopoietic stem cell transplantation for treatment of malignant hematological disease. Aizheng. 2006;25(8):1019-1022.
12. Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107(8):3065-3073.
13. Russell JA, Turner AR, Larratt L, et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transplant. 2007;13(3):299-306.
14. Yan HM, Ji SQ, Wang HX, et al. Effect of anti-CD25 monoclonal antibody for prophylaxis and therapy of acute GVHD and immune reconstitution following HLA haplotype related T-cell undepleted allogeneic bone marrow transplantation. Zhonghua Qiguan Yizhi Zazhi. 2006;27(60):341-344.
15. Korbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood. 2001;98(10):2900-2908.
16. Mengarelli A, Iori AP, Romano A, et al. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. Haematologica. 2003;88(3):315-323.
17. Schmid C, Labopin M, Nagler A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia:a retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukamia working party. J Clin Oncol. 2007;25(31):4938-4945.
18. Huang XJ, Liu DH, Liu KY, et al. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica. 2007;92(3):414-417
19. Bensinger W. Stem Cell Trialists' Collaborative Group. Individual patient data meta-analysis of allogeneic peripheral blood stem cell transplant vs bone marrow transplant in the management of hematological malignancies: indirect assessment of the effect of day 11 methotrexate administration. Bone Marrow Transplant. 2006;38(8):539-546.